Home / Market News / $KOD
benzinga Corporate Catalyst Impact 95/100 ● neutral

Kodiak Sciences To Host Webcast To Report Phase 3 DAYBREAK Topline Results For Wet AMD Candidates On September 28 At 8:30 AM Eastern Time

Sep 25, 2026, 10:03 PM UTC · Primary ticker $KOD

Kodiak Sciences will announce crucial Phase 3 DAYBREAK trial results for its wet AMD candidates, Zenkuda and KSI-501, on September 28. This event is a major catalyst for the company, as the success or failure of these trials will significantly impact its future valuation and competitive position in the ophthalmology market.

Kodiak Sciences is set to release topline results from its Phase 3 DAYBREAK study for two wet AMD candidates, Zenkuda and KSI-501, on September 28, 2026. This is a critical event for the precommercial biotechnology company, as the success of these trials is paramount to its ability to bring these therapeutics to market and generate revenue. Positive results could lead to a significant short-term surge in KOD's stock price and enhance its long-term prospects, while negative results could cause a sharp decline and raise questions about the company's future. Traders should be aware of the binary nature of this event, as the outcome will directly impact KOD's valuation and competitive standing in the lucrative wet AMD treatment market.

$KOD neutral Upcoming Phase 3 trial results
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.